Related references
Note: Only part of the references are listed.Propranolol potentiates the anti-angiogenic effects and anti-tumor efficacy of chemotherapy agents: implication in breast cancer treatment
Eddy Pasquier et al.
Oncotarget (2015)
Preclinical analysis of resistance and cross-resistance to low-dose metronomic chemotherapy
Annabelle Chow et al.
INVESTIGATIONAL NEW DRUGS (2014)
Intermittent Metronomic Drug Schedule Is Essential for Activating Antitumor Innate Immunity and Tumor Xenograft Regression
Chong-Sheng Chen et al.
NEOPLASIA (2014)
Concentration- and schedule-dependent effects of chemotherapy on the angiogenic potential and drug sensitivity of vascular endothelial cells
Eddy Pasquier et al.
ANGIOGENESIS (2013)
Dose selection trial of metronomic oral vinorelbine monotherapy in patients with metastatic cancer: a hellenic cooperative oncology group clinical translational study
Evangelos Briasoulis et al.
BMC CANCER (2013)
Adjuvant pegylated liposomal doxorubicin for older women with endocrine nonresponsive breast cancer who are NOT suitable for a standard chemotherapy regimen: The CASA randomized trial
Diana Crivellari et al.
BREAST (2013)
Preclinical recapitulation of antiangiogenic drug clinical efficacies using models of early or late stage breast cancer metastatis*
Robert S. Kerbel et al.
BREAST (2013)
β-blockers increase response to chemotherapy via direct antitumour and anti-angiogenic mechanisms in neuroblastoma
E. Pasquier et al.
BRITISH JOURNAL OF CANCER (2013)
A phase 1 trial of imatinib, bevacizumab, and metronomic cyclophosphamide in advanced colorectal cancer
R. K. Kelley et al.
BRITISH JOURNAL OF CANCER (2013)
Itraconazole and Arsenic Trioxide Inhibit Hedgehog Pathway Activation and Tumor Growth Associated with Acquired Resistance to Smoothened Antagonists
James Kim et al.
CANCER CELL (2013)
A mathematical model for the administration of temozolomide: comparative analysis of conventional and metronomic chemotherapy regimens
C. Faivre et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2013)
Center of Cancer Systems Biology Second Annual Workshop-Tumor Metronomics: Timing and Dose Level Dynamics
Philip Hahnfeldt et al.
CANCER RESEARCH (2013)
Formalizing an Integrative, Multidisciplinary Cancer Therapy Discovery Workflow
Mary F. McGuire et al.
CANCER RESEARCH (2013)
The Evolution of Melanoma Resistance Reveals Therapeutic Opportunities
Meghna Das Thakur et al.
CANCER RESEARCH (2013)
Oral Metronomic Chemotherapy in Recurrent, Metastatic and Locally Advanced Head and Neck Cancers
V. Patil et al.
CLINICAL ONCOLOGY (2013)
Clinical Pharmacogenetics Implementation Consortium Guidelines for Thiopurine Methyltransferase Genotype and Thiopurine Dosing: 2013 Update
M. V. Relling et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2013)
Drug repurposing in pediatrics and pediatric hematology oncology
Julie Blatt et al.
DRUG DISCOVERY TODAY (2013)
The person in personalised medicine
Francois Doz et al.
EUROPEAN JOURNAL OF CANCER (2013)
Safety and therapeutic effect of metronomic chemotherapy with cyclophosphamide and celecoxib in advanced breast cancer patients
Herman A. Perroud et al.
FUTURE ONCOLOGY (2013)
Ischaemia-induced mucus barrier loss and bacterial penetration are rapidly counteracted by increased goblet cell secretory activity in human and rat colon
Joep Grootjans et al.
GUT (2013)
Metronomic therapy is an effective salvage treatment for heavily pre-treated relapsed/refractory multiple myeloma
Xenofon Papanikolaou et al.
HAEMATOLOGICA (2013)
Preliminary evaluation of children treated with metronomic chemotherapy and valproic acid in a low-income country: Metro-Mali-02
F. Traore et al.
INDIAN JOURNAL OF CANCER (2013)
Oral metronomic scheduling of anticancer therapy-based treatment compared to existing standard of care in locally advanced oral squamous cell cancers: A matched-pair analysis
P. S. Pai et al.
INDIAN JOURNAL OF CANCER (2013)
Overcoming evasive resistance from vascular endothelial growth factor a inhibition in sarcomas by genetic or pharmacologic targeting of hypoxia-inducible factor 1 alpha
Yeo-Jung Kim et al.
INTERNATIONAL JOURNAL OF CANCER (2013)
Metronomic chemotherapy following the maximum tolerated dose is an effective anti-tumour therapy affecting angiogenesis, tumour dissemination and cancer stem cells
Marta Vives et al.
INTERNATIONAL JOURNAL OF CANCER (2013)
A phase II study of metronomic oral vinorelbine administered in the second line and beyond in non-small cell lung cancer (NSCLC): a phase II study of the Hellenic Oncology Research Group
Emmanouil Kontopodis et al.
JOURNAL OF CHEMOTHERAPY (2013)
The combination of intravenous bevacizumab and metronomic oral cyclophosphamide is an effective regimen for platinum-resistant recurrent ovarian cancer
Emma L. Barber et al.
JOURNAL OF GYNECOLOGIC ONCOLOGY (2013)
Cooperativity of CD44 and CD49d in Leukemia Cell Homing, Migration, and Survival Offers a Means for Therapeutic Attack
Vibuthi Singh et al.
JOURNAL OF IMMUNOLOGY (2013)
Prospective study of carmustine wafers in combination with 6-month metronomic temozolomide and radiation therapy in newly diagnosed glioblastoma: preliminary results Clinical article
Andrea Salmaggi et al.
JOURNAL OF NEUROSURGERY (2013)
Maximum tolerated dose versus metronomic scheduling in the treatment of metastatic cancers
Sebastien Benzekry et al.
JOURNAL OF THEORETICAL BIOLOGY (2013)
Has the time come for metronomics in low-income and middle-income countries?
Nicolas Andre et al.
LANCET ONCOLOGY (2013)
Oncolytic Adenovirus With Temozolomide Induces Autophagy and Antitumor Immune Responses in Cancer Patients
Ilkka Liikanen et al.
MOLECULAR THERAPY (2013)
Chemotherapy-triggered cathepsin B release in myeloid-derived suppressor cells activates the Nlrp3 inflammasome and promotes tumor growth
Melanie Bruchard et al.
NATURE MEDICINE (2013)
Phase II trial of continuous low-dose temozolomide for patients with recurrent malignant glioma
Antonio Omuro et al.
NEURO-ONCOLOGY (2013)
A pilot study of low-dose anti-angiogenic chemotherapy in combination with standard multiagent chemotherapy for patients with newly diagnosed metastatic Ewing sarcoma family of tumors: A Children's Oncology Group (COG) Phase II study NCT00061893
Judy L. Felgenhauer et al.
PEDIATRIC BLOOD & CANCER (2013)
The Combination of a Low-Dose Chemotherapeutic Agent, 5-Fluorouracil, and an Adenoviral Tumor Vaccine Has a Synergistic Benefit on Survival in a Tumor Model System
Sean M. Geary et al.
PLOS ONE (2013)
Pharmacogenetics and pharmacogenomics: a bridge to individualized cancer therapy
Liming Weng et al.
PHARMACOGENOMICS (2013)
A Comprehensive Gene Expression Analysis of Resistance Formation upon Metronomic Cyclophosphamide Therapy
Rebekka Kubisch et al.
TRANSLATIONAL ONCOLOGY (2013)
A Drug Repositioning Approach Identifies Tricyclic Antidepressants as Inhibitors of Small Cell Lung Cancer and Other Neuroendocrine Tumors
Nadine S. Jahchan et al.
CANCER DISCOVERY (2013)
Combining conventional chemotherapy and γδ T cell-based immunotherapy to target cancer-initiating cells
Matilde Todaro et al.
ONCOIMMUNOLOGY (2013)
Autologous lysate-pulsed dendritic cell vaccination followed by adoptive transfer of vaccine-primed ex vivo co-stimulated T cells in recurrent ovarian cancer
Lana E. Kandalaft et al.
ONCOIMMUNOLOGY (2013)
Multicenter Phase II Study of a New Effective S-1 and Irinotecan Combination Schedule in Patients with Unresectable Metastatic or Recurrent Colorectal Cancer
Yutaka Ogata et al.
CLINICAL MEDICINE INSIGHTS-ONCOLOGY (2013)
Clinical, pharmacokinetic and pharmacodynamic evaluations of metronomic UFT and cyclophosphamide plus celecoxib in patients with advanced refractory gastrointestinal cancers
Giacomo Allegrini et al.
ANGIOGENESIS (2012)
Network-enabled gene expression analysis
David Edwards et al.
BMC BIOINFORMATICS (2012)
Increased mean corpuscular volume of red blood cells predicts response to metronomic capecitabine and cyclophosphamide in combination with bevacizumab
Silvia Dellapasqua et al.
BREAST (2012)
Combination antiangiogenic therapy in advanced breast cancer: a phase 1 trial of vandetanib, a VEGFR inhibitor, and metronomic chemotherapy, with correlative platelet proteomics
Erica L. Mayer et al.
BREAST CANCER RESEARCH AND TREATMENT (2012)
Oral Metronomic Cyclophosphamide and Methotrexate Plus Fulvestrant in Advanced Breast Cancer Patients: A Mono-Institutional Case-Cohort Report
Gaetano Aurilio et al.
BREAST JOURNAL (2012)
Metronomic chemotherapy with cyclophosphamide and dexamethasone in patients with metastatic carcinoma of the prostate
P. D. Dickinson et al.
BRITISH JOURNAL OF CANCER (2012)
A phase I trial of oral metronomic vinorelbine plus capecitabine in patients with metastatic breast cancer
Zacharenia Saridaki et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2012)
An all-oral combination of metronomic cyclophosphamide plus capecitabine in patients with anthracycline- and taxane-pretreated metastatic breast cancer: a phase II study
Zhonghua Wang et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2012)
Metronomic oral combination chemotherapy with capecitabine and cyclophosphamide: a phase II study in patients with HER2-negative metastatic breast cancer
Masataka Yoshimoto et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2012)
Protracted low dose of oral vinorelbine and temozolomide with whole-brain radiotherapy in the treatment for breast cancer patients with brain metastases
Raffaele Addeo et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2012)
Metastatic melanoma patients treated with dendritic cell vaccination, Interleukin-2 and metronomic cyclophosphamide: results from a phase II trial
Eva Ellebaek et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2012)
Chemoresistance to Temozolomide in Human Glioma Cell Line U251 is Associated with Increased Activity of O 6-methylguanine-DNA Methyltransferase and Can be Overcome by Metronomic Temozolomide Regimen
Qiang Pan et al.
CELL BIOCHEMISTRY AND BIOPHYSICS (2012)
Metronomic Chemotherapy Combined With Bevacizumab and Erlotinib in Patients With Metastatic HER2-Negative Breast Cancer: Clinical and Biological Activity
Emilia Montagna et al.
CLINICAL BREAST CANCER (2012)
A Phase I Study of Veliparib in Combination with Metronomic Cyclophosphamide in Adults with Refractory Solid Tumors and Lymphomas
Shivaani Kummar et al.
CLINICAL CANCER RESEARCH (2012)
Phase II trial of a metronomic schedule of docetaxel and capecitabine with concurrent celecoxib in patients with prior anthracycline exposure for metastatic breast cancer
S. D. Young et al.
CURRENT ONCOLOGY (2012)
Combination treatment with metronomic temozolomide, bevacizumab and long-acting octreotide for malignant neuroendocrine tumours
Anna Koumarianou et al.
ENDOCRINE-RELATED CANCER (2012)
Efficacy and safety of low-dose metronomic chemotherapy with capecitabine in heavily pretreated patients with metastatic breast cancer
P. Fedele et al.
EUROPEAN JOURNAL OF CANCER (2012)
Phase II study of vinorelbine and continuous low doses cyclophosphamide in children and young adults with a relapsed or refractory malignant solid tumour: Good tolerance profile and efficacy in rhabdomyosarcoma - A report from the Societe Francaise des Cancers et leucemies de l'Enfant et de l'adolescent (SFCE)
Veronique Minard-Colin et al.
EUROPEAN JOURNAL OF CANCER (2012)
Phase II study of weekly paclitaxel and sorafenib as second/third-line therapy in patients with adrenocortical carcinoma
Alfredo Berruti et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2012)
Interaction between regulatory T cells and cancer stem cells
Xiaozhou Yu et al.
INTERNATIONAL JOURNAL OF CANCER (2012)
Circulating thrombospondin 1 level as a surrogate marker in patients receiving cyclophosphamide-based metronomic chemotherapy
Amelie Lansiaux et al.
INVESTIGATIONAL NEW DRUGS (2012)
Evaluation of oral chemotherapy with capecitabine and cyclophosphamide plus thalidomide and prednisone in prostate cancer patients
Li-Juan Meng et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2012)
Paclitaxel promotes differentiation of myeloid-derived suppressor cells into dendritic cells in vitro in a TLR4-independent manner
Tillmann Michels et al.
JOURNAL OF IMMUNOTOXICOLOGY (2012)
Residual dormant cancer stem-cell foci are responsible for tumor relapse after antiangiogenic metronomic therapy in hepatocellular carcinoma xenografts
Ines Martin-Padura et al.
LABORATORY INVESTIGATION (2012)
Low-Dose Metronomic Oral Dosing of a Prodrug of Gemcitabine (LY2334737) Causes Antitumor Effects in the Absence of Inhibition of Systemic Vasculogenesis
Giulio Francia et al.
MOLECULAR CANCER THERAPEUTICS (2012)
The secret ally: immunostimulation by anticancer drugs
Lorenzo Galluzzi et al.
NATURE REVIEWS DRUG DISCOVERY (2012)
Neurocognitive function after radiotherapy for paediatric brain tumours
Laetitia Padovani et al.
NATURE REVIEWS NEUROLOGY (2012)
Pioglitazone, etoricoxib, interferon-α, and metronomic capecitabine for metastatic renal cell carcinoma: final results of a prospective phase II trial
B. Walter et al.
MEDICAL ONCOLOGY (2012)
Capecitabine metronomic chemotherapy for palliative treatment of elderly patients with advanced gastric cancer after fluoropyrimidine-based chemotherapy
ShengLi He et al.
MEDICAL ONCOLOGY (2012)
Addition of an induction regimen of antiangiogenesis and antitumor immunity to standard chemotherapy improves survival in advanced malignancies
Eduardo Lasalvia-Prisco et al.
MEDICAL ONCOLOGY (2012)
Generalized principles of stochasticity can be used to control dynamic heterogeneity
David Liao et al.
PHYSICAL BIOLOGY (2012)
Metronomic Chemotherapy with the COMBAT Regimen in Advanced Pediatric Malignancies: A Multicenter Experience
D. Zapletalova et al.
ONCOLOGY (2012)
Metronomic Oral Cyclophosphamide in Patients with Advanced Solid Tumors
Peter Bojko et al.
ONKOLOGIE (2012)
Antiangiogenic metronomic therapy for children with recurrent embryonal brain tumors
Andreas Peyrl et al.
PEDIATRIC BLOOD & CANCER (2012)
Control Dominating Subclones for Managing Cancer Progression and Posttreatment Recurrence by Subclonal Switchboard Signal: Implication for New Therapies
Shengwen Calvin Li et al.
STEM CELLS AND DEVELOPMENT (2012)
Immunotherapy with HER-2 and VEGF peptide mimics plus metronomic paclitaxel causes superior antineoplastic effects in transplantable and transgenic mouse models of human breast cancer
Kevin C. Foy et al.
ONCOIMMUNOLOGY (2012)
Single low-dose cyclophosphamide combined with interleukin-12 gene therapy is superior to a metronomic schedule in inducing immunity against colorectal carcinoma in mice
Mariana Malvicini et al.
ONCOIMMUNOLOGY (2012)
Metronomic chemotherapy in metastatic breast cancer: Impact on VEGF
Lobna R. Ezz El-Arab et al.
JOURNAL OF THE EGYPTIAN NATIONAL CANCER INSTITUTE (2012)
Antiangiogenic combination therapy after local radiotherapy with topotecan radiosensitizer improved quality of life for children with inoperable brainstem gliomas
Sanna-Maria Kivivuori et al.
ACTA PAEDIATRICA (2011)
Pegylated liposomal doxorubicin in combination with low-dose metronomic cyclophosphamide as preoperative treatment for patients with locally advanced breast cancer
Silvia Dellapasqua et al.
BREAST (2011)
Continuous low-dose cyclophosphamide and methotrexate combined with celecoxib for patients with advanced cancer
O. A. Khan et al.
BRITISH JOURNAL OF CANCER (2011)
Molecular determinants of immunogenic cell death elicited by anticancer chemotherapy
Oliver Kepp et al.
CANCER AND METASTASIS REVIEWS (2011)
Phase II trial of bevacizumab and dose/dense chemotherapy with cisplatin and metronomic daily oral etoposide in advanced non-small-cell-lung cancer patients
Pierpaolo Correale et al.
CANCER BIOLOGY & THERAPY (2011)
A multicenter phase I trial of metronomic oral vinorelbine plus cisplatin in patients with NSCLC
Athanasios G. Pallis et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2011)
Phase I trial of metronomic oral vinorelbine in patients with advanced cancer
Lakshmi Rajdev et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2011)
Metronomic Oral Topotecan with Pazopanib Is an Active Antiangiogenic Regimen in Mouse Models of Aggressive Pediatric Solid Tumor
Sushil Kumar et al.
CLINICAL CANCER RESEARCH (2011)
Multihistology, Target-Driven Pilot Trial of Oral Topotecan as an Inhibitor of Hypoxia-Inducible Factor-1α in Advanced Solid Tumors
Shivaani Kummar et al.
CLINICAL CANCER RESEARCH (2011)
Feasibility of metronomic oral cyclophosphamide plus prednisolone in elderly patients with inoperable or metastatic soft tissue sarcoma
Olivier Mir et al.
EUROPEAN JOURNAL OF CANCER (2011)
Combination of lentivector immunization and low-dose chemotherapy or PD-1/PD-L1 blocking primes self-reactive T cells and induces anti-tumor immunity
Sophie R. Sierro et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2011)
Suppression of hepatic tumor growth and metastasis by metronomic therapy in a rat model of hepatocellular carcinoma
Jeong Won Jang et al.
EXPERIMENTAL AND MOLECULAR MEDICINE (2011)
Metronomic scheduling of anticancer treatment: the next generation of multitarget therapy?
Nicolas Andre et al.
FUTURE ONCOLOGY (2011)
A randomized phase III trial of IV carboplatin and paclitaxel x 3 courses followed by observation versus weekly maintenance low-dose paclitaxel in patients with early-stage ovarian carcinoma: A Gynecologic Oncology Group Study
Robert S. Mannel et al.
GYNECOLOGIC ONCOLOGY (2011)
Looking at the Seemingly Contradictory Role of Vinblastine in Anaplastic Large-Cell Lymphoma From a Metronomic Perspective
Nicolas Andre et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Capecitabine Versus Classical Cyclophosphamide, Methotrexate, and Fluorouracil As First-Line Chemotherapy for Advanced Breast Cancer
Martin R. Stockler et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Phase II study of metronomic chemotherapy with bevacizumab for recurrent glioblastoma after progression on bevacizumab therapy
David A. Reardon et al.
JOURNAL OF NEURO-ONCOLOGY (2011)
Nontoxic, Fiscally Responsible, Future of Oncology: Could it be Beginning in the Third World?
Giannoula Lakka Klement et al.
JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY (2011)
Children Treated With Metronomic Chemotherapy in a Low-income Country: METRO-MALI-01
Traore Fousseyni et al.
JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY (2011)
A Phase II Randomized Trial of Gefitinib Alone or with Tegafur/Uracil Treatment in Patients with Pulmonary Adenocarcinoma Who had Failed Previous Chemotherapy
Yuh-Min Chen et al.
JOURNAL OF THORACIC ONCOLOGY (2011)
Chemotherapy Dosing Schedule Influences Drug Resistance Development in Ovarian Cancer
Raquel De Souza et al.
MOLECULAR CANCER THERAPEUTICS (2011)
Immunological Effects of Low-dose Cyclophosphamide in Cancer Patients Treated With Oncolytic Adenovirus
Vincenzo Cerullo et al.
MOLECULAR THERAPY (2011)
Integrating pharmacogenetics into gemcitabine dosing-time for a change?
Joseph Ciccolini et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2011)
Drug-Tolerant Cancer Cells Show Reduced Tumor-Initiating Capacity: Depletion of CD44+ Cells and Evidence for Epigenetic Mechanisms
Hong Yan et al.
PLOS ONE (2011)
A Phase II Study of Metronomic Oral Topotecan for Recurrent Childhood Brain Tumors
Jane E. Minturn et al.
PEDIATRIC BLOOD & CANCER (2011)
Embryonal Rhabdomyosarcoma With Metastases Confined to the Lungs: Report From the CWS Study Group
Tobias M. Dantonello et al.
PEDIATRIC BLOOD & CANCER (2011)
A Phase I Study of Zoledronic Acid and Low-Dose Cyclophosphamide in Recurrent/Refractory Neuroblastoma: A New Approaches to Neuroblastoma Therapy (NANT) Study
Heidi V. Russell et al.
PEDIATRIC BLOOD & CANCER (2011)
Salvage Therapy With Oral Metronomic Cyclophosphamide and Methotrexate for Castration-refractory Metastatic Adenocarcinoma of the Prostate Resistant to Docetaxel
Vittorio Gebbia et al.
UROLOGY (2011)
Chemotherapeutic agents in low noncytotoxic concentrations increase immunogenicity of human colon cancer cells
Ramon Kaneno et al.
CELLULAR ONCOLOGY (2011)
Tumors That Acquire Resistance to Low-Dose Metronomic Cyclophosphamide Retain Sensitivity to Maximum Tolerated Dose Cyclophosphamide
Urban Emmenegger et al.
NEOPLASIA (2011)
Metronomic Cyclophosphamide andMethotrexate Chemotherapy Combined with 1E10 Anti-Idiotype Vaccine in Metastatic Breast Cancer
Jorge L. Soriano et al.
INTERNATIONAL JOURNAL OF BREAST CANCER (2011)
Efficacy and Tolerability of Vinorelbine in the Cancer Therapy
Giuseppina Galano et al.
CURRENT DRUG SAFETY (2011)
Optimising the dose of capecitabine in metastatic breast cancer: confused, clarified or confirmed?
C. Zielinski et al.
ANNALS OF ONCOLOGY (2010)
Metronomic gemcitabine suppresses tumour growth, improves perfusion, and reduces hypoxia in human pancreatic ductal adenocarcinoma
K. K. Y. Cham et al.
BRITISH JOURNAL OF CANCER (2010)
A Phase 2 Pilot Trial of Low-Dose, Continuous Infusion, or Metronomic Paclitaxel and Oral Celecoxib in Patients With Metastatic Melanoma
Rupal S. Bhatt et al.
CANCER (2010)
Selective Depletion of CD4+CD25+Foxp3+ Regulatory T Cells by Low-Dose Cyclophosphamide Is Explained by Reduced Intracellular ATP Levels
Jie Zhao et al.
CANCER RESEARCH (2010)
Knockout of HIF-1α in tumor-associated macrophages enhances M2 polarization and attenuates their pro-angiogenic responses
Christian Werno et al.
CARCINOGENESIS (2010)
A multi-centre Canadian pilot study of metronomic temozolomide combined with radiotherapy for newly diagnosed paediatric brainstem glioma
Julia R. Sharp et al.
EUROPEAN JOURNAL OF CANCER (2010)
The influence of TXNDC5 gene on gastric cancer cell
Lin Zhang et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2010)
Vinblastine in Children and Adolescents With High-Risk Anaplastic Large-Cell Lymphoma: Results of the Randomized ALCL99-Vinblastine Trial
Marie-Cecile Le Deley et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Phase II study of combining sorafenib with metronomic tegafur/uracil for advanced hepatocellular carcinoma
Chih-Hung Hsu et al.
JOURNAL OF HEPATOLOGY (2010)
In vivo chemoresistance of prostate cancer in metronomic cyclophosphamide therapy
Lilja Thoenes et al.
JOURNAL OF PROTEOMICS (2010)
Metronomic Gemcitabine in Combination with Sunitinib Inhibits Multisite Metastasis and Increases Survival in an Orthotopic Model of Pancreatic Cancer
Hop S. Tran Cao et al.
MOLECULAR CANCER THERAPEUTICS (2010)
Potent Preclinical Impact of Metronomic Low-Dose Oral Topotecan Combined with the Antiangiogenic Drug Pazopanib for the Treatment of Ovarian Cancer
Kae Hashimoto et al.
MOLECULAR CANCER THERAPEUTICS (2010)
Activity of a multitargeted chemo-switch regimen (sorafenib, gemcitabine, and metronomic capecitabine) in metastatic renal-cell carcinoma: a phase 2 study (SOGUG-02-06)
Joaquim Bellmunt et al.
LANCET ONCOLOGY (2010)
Metronomic Chemotherapy Enhances Antitumor Effects of Cancer Vaccine by Depleting Regulatory T Lymphocytes and Inhibiting Tumor Angiogenesis
Chi-An Chen et al.
MOLECULAR THERAPY (2010)
Metronomic chemotherapy: new rationale for new directions
Eddy Pasquier et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2010)
Bevacizumab plus Low-Dose Metronomic Oral Cyclophosphamide in Heavily Pretreated Patients with Recurrent Ovarian Cancer
Alfonso Sanchez-Munoz et al.
ONCOLOGY (2010)
Instructive role of the vascular niche in promoting tumour growth and tissue repair by angiocrine factors
Jason M. Butler et al.
NATURE REVIEWS CANCER (2010)
Treg depletion with a low-dose metronomic temozolomide regimen in a rat glioma model
Claire Banissi et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2009)
Comparative Impact of Trastuzumab and Cyclophosphamide on HER-2-Positive Human Breast Cancer Xenografts
Giulio Francia et al.
CLINICAL CANCER RESEARCH (2009)
Increased Tumor Oxygenation and Drug Uptake During Anti-Angiogenic Weekly Low Dose Cyclophosphamide Enhances the Anti-Tumor Effect of Weekly Tirapazamine
J. C. Doloff et al.
CURRENT CANCER DRUG TARGETS (2009)
Single-Drug Vinblastine As Salvage Treatment for Refractory or Relapsed Anaplastic Large-Cell Lymphoma: A Report From the French Society of Pediatric Oncology
Laurence Brugieres et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Oral Uracil and Tegafur Compared With Classic Cyclophosphamide, Methotrexate, Fluorouracil As Postoperative Chemotherapy in Patients With Node-Negative, High-Risk Breast Cancer: National Surgical Adjuvant Study for Breast Cancer 01 Trial
Toru Watanabe et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Chemomodulation of human dendritic cell function by antineoplastic agents in low noncytotoxic concentrations
Ramon Kaneno et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2009)
A change of strategy in the war on cancer
Robert A. Gatenby
NATURE (2009)
For cancer, seek and destroy or live and let live?
Nicolas Andre et al.
NATURE (2009)
Treating Childhood Acute Lymphoblastic Leukemia without Cranial Irradiation
Ching-Hon Pui et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
被撤回的出版物: Anthracycline chemotherapy inhibits HIF-1 transcriptional activity and tumor-induced mobilization of circulating angiogenic cells (Retracted article. See vol. 119, 2022)
KangAe Lee et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
Using pharmacokinetic and pharmacodynamic modeling and simulation to evaluate importance of schedule in topotecan therapy for pediatric neuroblastoma
John C. Panetta et al.
CLINICAL CANCER RESEARCH (2008)
A Phase II Trial of Erlotinib in Combination with Bevacizumab in Patients with Metastatic Breast Cancer
Maura N. Dickler et al.
CLINICAL CANCER RESEARCH (2008)
Immunogenic cancer cell death: a key-lock paradigm
Antoine Tesniere et al.
CURRENT OPINION IN IMMUNOLOGY (2008)
The anticancer immune response: indispensable for therapeutic success?
Laurence Zitvogel et al.
JOURNAL OF CLINICAL INVESTIGATION (2008)
The prince and the pauper. A tale of anticancer targeted agents
Alfonso Duenas-Gonzalez et al.
MOLECULAR CANCER (2008)
Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer
Kathy Miller et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine
Shinichi Sakuramoto et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Differential expression of mimecan and thioredoxin domain-containing protein 5 in colorectal adenoma and cancer: A proteomic study
Yinghong Wang et al.
EXPERIMENTAL BIOLOGY AND MEDICINE (2007)
Phase II study of metronomic chemotherapy for recurrent malignant gliomas in adults
Santosh Kesari et al.
NEURO-ONCOLOGY (2007)
Metronomic cyclophosphamide regimen selectively depletes CD4+ CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients
Francois Ghiringhelli et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2007)
Cancer immunologists and cancer biologists: Why we didn't talk then but need to now
George C. Prendergast et al.
CANCER RESEARCH (2007)
Anticancer therapies combining antiangiogenic and tumor cell cytotoxic effects reduce the tumor stem-like cell fraction in glioma xenograft tumors
Chris Folkins et al.
CANCER RESEARCH (2007)
Metronomic chemotherapy:: an antiangiogenic scheduling
B. Laquente et al.
CLINICAL & TRANSLATIONAL ONCOLOGY (2007)
Targeting Microtubules to inhibit angiogenesis and disrupt tumour vasculature: Implications for cancer treatment
Eddy Pasquier et al.
CURRENT CANCER DRUG TARGETS (2007)
A pilot pharmacokinetic and antiangiogenic biomarker study of celecoxib and low-dose metronomic vinblastine or cyclophosphamide in pediatric recurrent solid tumors
Diana Stempak et al.
JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY (2006)
Therapy-induced acute recruitment of circulating endothelial progenitor cells to tumors
Yuval Shaked et al.
SCIENCE (2006)
Safety and pharmacokinetics of temozolomide using a dose-escalation, metronomic schedule in recurrent paediatric brain tumours
S. Baruchel et al.
EUROPEAN JOURNAL OF CANCER (2006)
Randomized phase II trial of letrozole and letrozole plus low-dose metronomic oral cyclophosphamide as primary systemic treatment in elderly breast cancer patients
Alberto Bottini et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Circulating endothelial-cell kinetics and viability predict survival in breast cancer patients receiving metronomic chemotherapy
Patrizia Mancuso et al.
BLOOD (2006)
Low-dose metronomic daily cyclophosphamide and weekly tirapazamine: A well-tolerated combination regimen with enhanced efficacy that exploits tumor hypoxia
U Emmenegger et al.
CANCER RESEARCH (2006)
Anti-angiogenic treatment of breast cancer using metronomic low-dose chemotherapy
R Munoz et al.
BREAST (2005)
Optimal biologic dose of metronomic chemotherapy regimens is associated with maximum antiangiogenic activity
Y Shaked et al.
BLOOD (2005)
A feasibility trial of antiangiogenic (Metronomic) chemotherapy in pediatric patients with recurrent or progressive cancer
MW Kieran et al.
JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY (2005)
Repopulation of cancer cells during therapy: An important cause of treatment failure
JJ Kim et al.
NATURE REVIEWS CANCER (2005)
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma
R Stupp et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
A multitargeted, metronomic, and maximum-tolerated dose chemo-switch regimen is antiangiogenic, producing objective responses and survival benefit in a mouse model of cancer
K Pietras et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
UKT-04 trial of continuous metronomic low-dose chemotherapy with methotrexate and cyclophosphamide for recurrent glioblastoma
U Herrlinger et al.
JOURNAL OF NEURO-ONCOLOGY (2005)
A randomized trial of adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung
H Kato et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Drug repositioning: Identifying and developing new uses for existing drugs
TT Ashburn et al.
NATURE REVIEWS DRUG DISCOVERY (2004)
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer
H Hurwitz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
The anti-angiogenic basis of metronomic chemotherapy
RS Kerbel et al.
NATURE REVIEWS CANCER (2004)
Thrombospondin 1, a mediator of the antiangiogenic effects of low-dose metronomic chemotherapy
G Bocci et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
Metronomic therapy with cyclophosphamide and dexamethasone for prostate carcinoma
LM Glode et al.
CANCER (2003)
Vinorelbine in previously treated advanced childhood sarcomas - Evidence of activity in rhadhomyosarcoma
M Casanova et al.
CANCER (2002)
Low-dose oral methotrexate and cyclophosphamide in metastatic breast cancer: antitumor activity and correlation with vascular endothelial growth factor levels
M Colleoni et al.
ANNALS OF ONCOLOGY (2002)
Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity
G Klement et al.
JOURNAL OF CLINICAL INVESTIGATION (2000)
Share Paper
